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Abstract (248/250 words) 
Background: Previous systematic reviews have found that nurses and pharmacists can 
provide equivalent, or higher, quality of care for some tasks performed by general 
practitioners (GPs) in primary care. There is a lack of economic evidence for this substitution.  
Aim: To explore the costs and outcomes of role substitution between GPs and nurses, 
pharmacists and allied health professionals in primary care.  
Design and setting: A systematic review of economic evaluations exploring role substitution 
of allied health professionals in primary care was conducted. Role substitution was defined as 
‘the substitution of work that was previously completed by a GP in the past and is now 
completed by a nurse or allied health professional’.  
Method: Databases searched: Medline, CINAHL, Cochrane Library, NICE and the Centre 
for Reviews and Dissemination database. The review followed guidance from the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).  
Results: Six economic evaluations were identified. There was some limited evidence that 
nurse-led care for common minor health problems was cost-effective compared with GP care, 
and that nurse-led interventions for chronic fatigue syndrome and pharmacy-led services for 
the medicines’ management of coronary heart disease and chronic pain were not. In Korea, 
community health nurse practitioners delivered primary care services for half the cost of 
physicians. There was a lack of economic evidence for role substitution by other groups of 
allied health professionals such as physiotherapists and occupational therapists.  
Conclusion:  There is limited economic evidence for role substitution in primary care; more 
economic evaluations are needed. 
Keywords: Primary health care, systematic review, economic evaluation, cost-effectiveness, 
role substitution, general practitioner, nursing practitioner, allied health professional 
How this fits in: Previous systematic reviews have found that nurses can provide equivalent, 
or higher, quality of care for some tasks performed by GPs. Evidence is lacking for role 
substitution in other allied health professional groups such as physiotherapists and 
occupational therapists. There is also a lack of economic evidence for this role substitution, 
and a number of reviews have concluded that future research should address this. Despite the 
shortage of evidence, role substitution is becoming commonplace in primary care.  





General practice in the UK faces challenges due to our ageing population and the increasing 
prevalence of chronic conditions. Additional pressures also come from advances in 
treatments and technologies and increased public expectations. As demand for general 
practice rises, workload pressures on GPs and their teams, increase. There is also a 
recruitment and retention crisis in the GP workforce. In 2016, it was estimated that the NHS 
in England were approximately 6500 GPs short - this shortage is estimated to rise to 12100 
by 2020.1 The use of nurses and other non-medical health professionals substituting for GPs 
has been proposed as a potential solution.2 Physician assistants are a new development in the 
NHS and have also been presented as a solution to medical staff shortages as they can 
diagnose, treat and refer patients autonomously.  
Previous systematic reviews have found that nurses can provide equivalent, or in some 
instances higher quality of care compared with GPs in primary care.3-6 Furthermore, previous 
reviews have also reported positive results for pharmacist substituting for GPs in primary 
care.7,8 Previous reviews have explored the economic impact of task shifting in primary care3-
6 but the majority of studies did not include full economic evaluations. A previous systematic 
review of economic evaluations explored the substitution of skills between health care 
professionals across a variety of settings including general practice, hospital and the 
community9 but most of the evidence included was of nurses substituting for GPs and only 
one study was in a general practice setting. Given the limited evidence for full economic 
evaluations and of allied health professionals, this systematic review focussed on full 
economic evaluations of role substitution including all allied health professionals with a focus 
on primary care and serves as a timely update of the evidence.   
 
The aims of this systematic review were to review economic evaluations of nurses and other 
allied health professionals working in primary care as substitutes for some of the tasks 
performed by general practitioners.  
 
Methods  
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Selection of studies 
Role substitution was defined as ‘the substitution of work that was previously completed by a 
general medical practitioner in the past and is now completed by a nurse or allied health 
professional’. Studies were excluded if the authors did not explicitly state within the paper 
that role substitution was taking place. To be included in the review, the study design of the 
included papers had to be a full economic evaluation, either cost-effectiveness, cost-benefit, 
cost-utility, cost-minimisation or cost-consequence analysis.  The population assessed was 
patients consulting in primary care; the intervention was role substitution by allied health 
professionals including nurses, pharmacists, physiotherapists and occupational therapists; the 
comparator was GP-led care; the outcomes were economic evaluations; and the setting was 
primary care.  
 
Identification of studies and quality assessment  
A comprehensive search was performed in OVID Medline, CINAHL, Cochrane Library, 
NICE, and the Centre for Reviews and Dissemination database. Search dates were from May 
19th 2017 to July 31st 2017.The search strategy performed in OVID Medline can be seen in 
Appendix 1. In order to recover a comprehensive set of relevant literature and to increase 
sensitivity, the searches were purposely broad. The search strategy included the terms ‘role 
substitution’, ‘task shifting’, ‘general practice’ and ‘primary care’. The ‘population’, 
‘comparator’ and ‘outcome’ elements were not included in the search strategy to avoid 
narrowing the strategy and subsequently limiting the search results. The search was not 
restricted by age, date or country of origin. Additional studies were identified through hand 
searching the reference lists of included studies and relevant reviews. This review conformed 
to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidance10 (Appendix 2 PRISMA checklist). Following the removal of duplicates, two 
reviewers independently screened titles and abstracts for relevance, subsequently full-paper 
screening was conducted to retrieve eligible papers (BFA, AS). Discrepancies were resolved 
through discussion. The same two reviewers independently assessed the quality of the 
included studies using the Drummond and colleagues’11 checklist for economic evaluations 
(Table 1).  
 
Data extraction  
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Key characteristics from the included study were extracted including sample size of the 
intervention groups being compared, number and location of practices, study design, type of 
economic evaluation and perspective, outcomes measured and main findings.  
Results  
After the removal of duplicates, the search identified 10,261 studies (Figure 1). Most of these 
were excluded because they did not explicitly state that role substitution had occurred, were 
not conducted in primary care setting, or were not full economic evaluations. Six studies were 
included in the review: three used cost-minimisation, two cost-utility and one cost-
effectiveness analysis (Table 2). Three studies were good quality and two were moderate 
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Table 1. Quality appraisal of economic evaluations of role substitution in primary care 







et al., (2010)13 
Lee et al., 
(2004)18 




Turner et al., 
(2008)12 
Was a well-defined question posed in an 
answerable form? 
      
Was a comprehensive description of the 
competing alternatives given 
   -  -  
Was the effectiveness of the programmes 
or services established? 
      
Were all the important and relevant costs 
and consequences for each alternative 
identified? 
-       
Were costs and consequences measured 
accurately in appropriate physical units? 
-       
Were costs and consequences valued 
credibly? 
      
Were costs and consequences adjusted for 
differential timing? 
N/A -  N/A N/A   
Was an incremental analysis of costs and 
consequences of alternatives performed? 
N/A N/A N/A    
Was allowance made for uncertainty in the 
establishments of costs and consequences? 
      
Did the presentation and discussion of 
study results include all issues of concern 
to users? 
      
Quality assessment score out of a possible 
10 (included questions answered N/A).  
7  9  9  8 9  9 
 
Note:  = yes;  = no; - = can’t tell, N/A = not applicable. 
Quality rating based on the number of Drummond questions answered: 0-5 = poor quality, 6-8 = moderate quality, 9+ = good quality 






Figure 1. Systematic review flow diagram  
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Table 2. Characteristics of included studies (n = 6) 






Lee et al.18 Neilson et al.17 Richardson et al.14 Turner et al.12  
Country of 
origin  
England  Netherlands  Korea  United Kingdom England  United Kingdom 
Aims  To assess the cost-





for patients with 
coronary heart disease.   
To assess the 





in treating common 
conditions. 
To assess community 
health practitioner 
services in primary 
care, and to assess the 
economic impact of 
these services. 
To measure the 
differences in mean costs 
and effects of a 
pharmacy-led service for 
the management of 
chronic pain in primary 
care. 
To assess the cost-
effectiveness of nurse-
led self-help treatments 
for patients with 
chronic fatigue 
syndrome/ myalgic 
encephalitis in primary 
care. 
To assess health 
service resource use 
of a nurse-led disease 
management for 
secondary prevention 
in patients with 
chronic heart disease 







Pharmacists  Nurse practitioners Community health 
practitioners (CHPs) 
Pharmacists  Nurses Nurses 




Random sampling of 
CHPs working in 
community health 
posts 















Cost-utility analysis  Cost-effectiveness 
analysis  





and health status 
(measured using the 
SF-36 and EQ-5D). 
Direct costs within 
the healthcare 
sector and costs 
outside the 
healthcare sector 
Activity measures e.g. 
consultations and cost 
measures. 
Differences in mean total 
costs and effects (quality 
adjusted life years 
(QALYs)). 
Costs and health 
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Due to the heterogeneity of included studies, a narrative review is presented.  
 
Substitution by nurses  
Three economic evaluations investigated the cost-effectiveness of nurses substituting for 
GPs12-14 (Table 2). A good quality cost-utility analysis assessed health service resource use of 
a nurse-led disease management programme for secondary prevention in patients with 
chronic heart disease and heart failure in primary care, compared to usual GP care.12 Length 
of follow-up was 12 months. The nurse-led group was associated with higher costs relating to 
all categories of resource use, compared with the usual care group (p<0.001). A difference of 
0.03 QALY value was reported between the nurse-led group and usual care, and the cost per 
QALY gained in the nurse-led group was £13,158 (£17,694 2016/17 prices15). It is unclear 
whether there was a statistically significant difference in QALYs between the nurse-led 
disease management program and usual care, as confidence intervals were not reported in the 
paper (Table 3).  
         
A good quality cost-minimisation analysis conducted alongside a randomised controlled trial 
(RCT) compared the differences in costs between GPs and nurse practitioners (NPs) in 
treating common minor health problems.13 Cost-minimisation was used because the RCT 
found no significant differences in effectiveness between GPs and NPs. The study had a short 
follow-up period of two weeks. The costs of NP consultations were significantly lower than 
with GPs (p = 0.001) with a mean difference of €8.21, which equates to £7 inflated to 
2016/17 prices.15 Sensitivity analysis varying GP salary reported significantly lower costs of 
NP consultations when adjusting to the salary of an employed GP (p=0.007) or of a GP 
employed by other GPs in partnership (p=0.02).  
 
A good quality cost-effectiveness analysis of nurse-led pragmatic rehabilitation (PR), and 
supportive listening (SL), for patients with chronic fatigue syndrome was compared with 
treatment as usual (TAU) by GPs.14 Costs and outcomes were discounted at a rate of 3.5% 
per year; however, with no further detail of how this discounting was performed. Length of 
follow-up was 70 weeks and patients were asked to recall use of hospital services, day 
services and contacts made with health professionals during this period. TAU was slightly 
more effective than PR and SL, at a lower cost, when baseline differences in EQ-5D were 
adjusted. Richardson et al. reported that all confidence intervals for estimations of costs and 
effects crossed zero. Imputated results showed that PR = mean ICER QALY of -0.01 (95% 
Role substitution in general medical services 
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CI = -0.09, 0.07 and SL = mean ICER QALY of -0.04 (95% CI = -0.12, 0.04). SL was no 
more effective than PR or TAU, but costed more; therefore, SL was not found to be cost-
effective. Complete case analysis as part of sensitivity analyses showed PR was associated 
with slightly higher QALYs than TAU, but confidence intervals crossed zero. Complete case 
results found that PR = mean ICER QALY of -0.01 (95% CI = -0.08, 0.10) and SR = mean 
ICER QALY of -0.04 (95% CI = -0.13, 0.045. The nurse-led PR intervention produced a cost 
per QALY ratio of £39,583 (£44,812 inflated to 2016/1715). It was concluded that the nurse-
led PR intervention would not be deemed cost-effective in the UK at the current NICE 
threshold of £20-30,000 per QALY (Table 3).  
 
Substitution by pharmacists  
 
Two moderate quality economic evaluations assessed the substitution of medicines’ 
management by pharmacists instead of GPs16,17 (Table 2). A cost-minimisation analysis 
explored the cost-effectiveness of a comprehensive community pharmacy medicines 
management project16 service for patients with coronary heart disease. The study follow-up 
period was 12 months. Total NHS costs at baseline were £852 and £738 for the intervention 
and control group, respectively. The difference in costs between groups at baseline was £115 
(p<0.0001), (£139 inflated to 2016/17 prices15). Total NHS costs at follow-up were £971 and 
£835 for the intervention and control groups, respectively. Total NHS costs at follow-up for 
the pharmacist group were significantly greater than the control group (p<0.0001) with a 
mean difference in costs of £135 (£164 2016/17 prices15). This was due to the costs of 
providing the additional pharmacist training. The differences in QALYs between groups was 
0.04, this was non-significant (95% CI = -0.05, 0.13). An ICER was not presented in the 
paper.  
A cost-utility analysis of a pharmacy-led service for the management of chronic pain17 as part 
of a three –arm RCT compared pharmacist-led medication review with face to face 
pharmacist prescribing, pharmacist-led medication review with feedback to GP, and 
treatment as usual (TAU) from the GP. Study follow-up was 6 months. After baseline costs 
were adjusted, both pharmacy-led interventions were more costly than TAU. Relative to 
TAU, the adjusted mean costs differences per patient was £77 for prescribing (95% CI = -82, 
237) and £54 for medication review (95% CI = -103, 212). Relative to TAU, the adjusted 
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mean QALYs was 0.06 for prescribing (95% CI -0.01, 0.02) and 0.01 for medication review 
(95% CI = -0.01, 0.02). 
 
 
Community health practitioners  
A good quality cost-minimisation analysis from Korea compared the delivery of primary care 
services by community health practitioners (CHPs) in remote communities with equivalent 
care delivered by physicians in inner-city clinics (no CHP services)18 (Table 3). CHPs were 
described as registered nurses responsible for the delivery of primary care, who had received 
6 months of special training. The length of study follow-up was 6 months. The mean total 
cost of CHP services per month was $2423.7 (£2520 inflated to 2016/1715). The total mean 
costs of no CHP services was $5187.7 (£5394 in 2016/1715). Total mean costs were 
significantly lower for CHP services (p<0.001) with a cost ratio of 2.16 (SD=1.24, range = 
0.09 to 9.63). Indirect costs were also lower for CHP services group, due to travel costs and 
loss of earnings for patients in the physician group, who had to travel to inner city clinics to 
see a physician. 
Role substitution in general medical services 
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Table 3. Results of included studies (n=6) 
 






Dierick-van Daele et 
al.13 
Lee et al.18 Neilson et al.17 Richardson on et 
al.14 
Turner et al.12 
Year of publication 
and country  
2007; England 2010; Netherlands 2004; Korea 2015; United 
Kingdom 
2013; England 2008; United 
Kingdom 
Intervention groups 
compared, type of 








standard care from 
the GP in nine 
general practices. 
Intervention: nurse 
practitioners (n=12)  
Control: GPs (n=15); 
Role substitution of 
nurse practitioners by 





(n=600) Control: care 
delivered by 
physician; CHP 
services vs. no-CHP 
services in primary 
health care. Postal 
survey questionnaire 
sent to a sample of 








only (n=63). Control: 
treatment as usual 
from GP (n=63); 
Pharmacy-led care vs. 
treatment as usual for 
the management of 








(SL) (n=97). Control: 
Treatment as usual 





treatment as usual in 
186 general practices. 
Intervention: nurse-
led care (n=505) 




standard GP care in 
20 general practices. 








Cost-utility analysis  Cost-effectiveness 
analysis 
Cost-utility analysis  
Main outcomes 
measured, type of 
costs measured, type 
of outcomes 
measured 
Total NHS costs; 
Direct costs of 
delivering the 
intervention and NHS 
treatment costs (e.g. 
cost of medicines) 
and indirect costs of 
Costs of GP vs. nurse 
practitioner 
consultation; Direct 
costs within the 
healthcare sector and 
costs outside of the 
healthcare sector 
Total costs of care 
between CHP 
services model and 
no-CHP services 
model of care; Direct 
costs (e.g. personnel 
costs, materials) and 
Differences in mean 
total costs and effects 
of pharmacist-led 
management vs. GP-
led management of 
chronic pain; Direct 
costs, other costs 
Quality Adjusted Life 
Years (QALYs) 
derived from the 
EQ5D; Cost to the 
NHS (e.g. resource 
use and unit costs), 
private expenditures, 
Quality Adjusted Life 
Years (QALYs) 
derived from the EQ-
5D; Direct costs 
(including travel 
costs); Health utility 






and health status (SF-
36 and EQ-5D). 
(productivity losses); 
Process outcomes and 
outcomes of care. 
indirect costs 
(operational and 
depreciation costs) of 
CHP services. Direct 
costs (e.g. outpatient 
costs) and indirect 
costs (travel and loss 




efficacy of the 
intervention was 
based on previous 
findings. 
borne by patients and 
productivity losses; 
Health utility derived 
from SF-6D. 
informal care costs 









Not stated Practice and societal Not stated  NHS NHS and personal 
social services 
Patient and NHS 
Currency and Cost 
Year 
Pounds sterling 
derived from general 
practice –held 
records. Cost year not 
reported. 
Euros (€) derived 
using the price index 
of Statistics 
Netherlands for cost 
year 2006.   
Korean won (₩) 
converted to US 
dollars ($) derived 
from national unit 
costs for cost year 
1999 




Unit (PSSRU) and 
British National 
Formulary for prices 
at cost year 2009/10. 
Pounds sterling (£) 
derived from NHS 
reference costs and 
PSSRU at 2008/09 
prices. 
Pounds Sterling (£) 
derived from 
healthcare resource 
groups (HGRs) for 
cost year 2003-03 and 




Follow-up period 12 




varying GP salary. 
No discounting. 








were conducted with 
imputed values for 
SF-36 scores. 
Costs and outcomes 
were discounted at a 
rate of 3.5% per year. 
A complete case 
analysis as part of 
sensitivity analyses 
was conducted. 
Follow-up period 12 
months no 
discounting discount 
rate of 6% for 
equipment and 
training that would 
have an expected 
lifespan of more than 
one year. No 
sensitivity analysis 




and main findings 
Total NHS costs at 
baseline: intervention 
group £852.4, control 
group £737.8. Total 





(p<0.0001) in total 
NHS costs, due to the 
costs of providing 
pharmacists’ training. 
Mean difference in 
costs of £135.3 (£164 
inflated to 2016/17 
prices15). 
Cost per NP 
consultation €31.94. 
Cost per GP 
consultation €40.15; 
Lower direct 
consultation costs for 
NP compared with 
GP (p = 0.001) mean 
difference €8.21 (£7 
inflated to 2016/17 
prices15).   
Mean direct costs 
CHP $2423.7, SD: 
$565.6 (£252 inflated 
to 2016/17 prices15). 
Physician $5187.7, 
SD: $3262.5 (£5394 
inflated to 2016/17 
prices15). Mean 
indirect costs CHP 
($499.9, SD: $257.8) 
Physician ($1268.6, 
SD: $951.7); t-test 
found a significant 
difference in the 
average costs of care 
between the groups 
(p<0.001 cost ratio of 
2.16, with a range of 




£452 (£509 in 
2016/1715), 
medication review 
group £570 (£642 in 
2016/1715), TAU 
group £1333 (£1500 
in 2016/1715); Both 
pharmacy-led 
interventions were 
more costly, with 
slightly higher QALY 
gains than TAU.    
Excluding 
intervention costs of 
SL and PR, at 70 
week follow-up, total 
NHS cost of chronic 
fatigue syndrome 
£789 for PR, £916 for 
SL and £710 for 
TAU; TAU was 
slightly more 
effective than PR and 
SL, at a lower cost, 
when baseline 
differences in EQ-5D 
were adjusted. The 
nurse-led PR 
intervention produced 
a cost per QALY 
ratio of £39,583 
(inflated to £44,812 
in 2016/1715). 
Total mean NHS 
delivery costs nurse 
£1107.81 and GP 
£660.57, (p=0.001); 
A difference of 0.03 
QALY value was 
reported between the 
nurse-led group and 
usual care, and the 
cost per QALY 
gained in the nurse-
led group was 
£13,158 (£17,694 
inflated to 2016/17 
prices15). 
Conclusions No change in 
numbers of patients 
receiving appropriate 
treatment. Pharmacy-
led group more costly 
than standard care. 
Direct costs of 
consultations were 
lower for nurse 
practitioners than 
GPs. The differences 
in costs were mainly 
due to differences in 
salary. 
Care provided by a 
physician was twice 
as costly as the CHP 
services due to travel 
costs and loss of 
earnings for patients 
who would have had 
to travel to inner city 
clinics to see a 
physician. 
Pharmacy-led 
management is more 




with usual treatment. 
The nurse-led PR 
intervention was not 









Summary of main findings 
Nurse-led care for common, minor health conditions was as effective as and less costly than 
GP care. Nurse-led preventative care for secondary prevention of heart disease and heart 
failure was more costly and similar in effectiveness as usual GP care. It is uncertain whether 
there was a statistically significant difference in the QALY value reported between groups as 
confidence intervals were not reported in the paper. Nurse-led interventions for chronic 
fatigue syndrome were more costly and less effective. Pharmacy-led services for the 
medicines’ management of coronary heart disease was as effective as, but more costly than, 
GP care. For managing chronic pain, pharmacy-led care was slightly more effective than GP 
care for increased cost. In Korea community health nurse practitioners delivered primary care 
services for half the cost of physicians. There was a lack of economic evidence for role 
substitution by other groups of allied health professionals such as physiotherapists and 
occupational therapists.  
 
Strengths and weaknesses 
To our knowledge, this is the first systematic review that identifies full economic evaluations 
of the substitution of GPs by allied health professionals in a primary care setting. This review 
undertook extensive literature searches using a well-developed search strategy and robust 
methodology, and adhered to the PRISMA guidelines10. There were no restrictions on date of 
publication, or country of origin for the included studies. Economic evaluations conducted 
alongside RCTs are important as they produce reliable estimates of cost-effectiveness at low 
marginal cost.19 Of the six studies included in the review, five were concurrent economic 
evaluations alongside RCTs.12-14,16,17 
There were a number of limitations in the included studies. Consultation length was not 
considered in two of the economic evaluations that found role substitution to be cost-
effective.12,18 Although the results reported lower unit costs in these studies, nurse and CHP 
consultations may have been significantly longer than GP consultations, so actual costs may 
have been higher for the allied health professional groups. Only one of the included studies 
explicitly provided information on patient recall including contacts made with health care 
professionals over the study period.14 There was a lack of information regarding patient recall 
in the other included studies, making it difficult to ascertain how information on services 
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used by patients was gathered, whether the appropriate perspective was chosen to include all 
relevant costs, and whether the length of time horizon patients were asked to recall was 
appropriate. The Korean study may not be directly comparable to the UK and other countries 
with highly developed primary care services. There was a lack of explanatory detail when 
describing the intervention and control treatments, which might be improved by the inclusion 
of a concurrent process evaluation. For example, two studies provided only minimal 
information about usual GP care14,16 (Appendix 3). In addition, the economic evaluation 
method can be criticised where no significant differences in outcomes were found between 
groups, and a cost-minimisation analysis was conducted.16 Given the lack of a statistically 
significant effect, a cost-consequence analysis may have been more appropriate. There were 
inconsistencies in the reporting of findings of the included studies, for example ICER 
calculations and CIs around small differences in QALYs which make interpreting results 
difficult. In one study12 authors’ conclusions are not supported by their findings. Despite the 
higher service use costs reported substituting nurses for GPs, the authors concluded that the 
nurse-led disease management programme was costs-effective as it fell below the NICE cost-
effectiveness threshold of £20-£30,000 per QALY. However, this finding does not provide 
clear evidence of cost-effectiveness for this intervention given it was more costly than GP-led 
care. Also there was a lack of clarity about the perspective adopted, with two studies not 
providing this information (Appendix 3). This lack of clarity makes it difficult to ascertain 
whether all pertinent costs and outcomes were included in the analysis. Additionally, only 
two of the included studies12,14 produced a cost-effectiveness acceptability curve.  
There were disparities between the country and the type of role substitution that took place in 
the included studies. This review used a specific definition of role substitution; however, 
there were difficulties distinguishing true role substitution in the included studies which 
makes generalisability difficult. The majority of the included studies assessed novel allied 
health professional-led interventions, these studies represent a different kind of role 
substitution whereby allied health professionals are used to replace GP-led care. When 
reviewing the literature the definition of role substitution was used to uncover economic 
literature of allied health professionals performing care in place of a GP. In order to better 
inform current policy with regards to increasing the involvement of allied health 
professionals in primary care, future studies should assess the cost-effectiveness of all forms 
of role substitution to better understand the impact of such workforce redesign. From the 
included studies, generalisability of results is difficult as each study assessed different allied 
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health professionals, used different interventions, outcome measures and time horizons. 
There is a larger evidence base for role substitution with nurses, in order to improve the 
generalisability of role substitution with other allied health professionals further evidence is 
needed. Finally, the majority of papers were within a one year time horizon (70 week time 
horizon in one study), none of the studies extrapolated beyond this. Given the range of 
interventions it would have been useful for the authors to justify their chosen time horizon in 
order to assess if this was appropriate and relevant for expected outcomes resulting from the 
intervention. A new, innovative service redesign such as role substitution in primary care 
may not necessarily show changes in the immediate term; therefore, future studies with 
longer time horizons are recommended.  
 
Comparison with previous literature 
The evidence reported by previous systematic reviews only reported the economic impact of 
role substitution of GPs by nurses and pharmacists in terms of their costs. These are not 
considered full economic evaluations as they do not synthesise costs and outcomes.3-8  
In 2008, Dierick-van Daele et al. reviewed economic evaluations of the substitution of skills 
between health professionals in a variety of settings including general practice, hospital and 
community settings. However, the majority of the evidence looked at nurses and only one of 
the included studies took place in general practices.20 Dierick-van Daele and colleagues stated 
this paper was an economic evaluation, but this study did not compare costs and outcomes, 
and therefore would not be considered a full economic evaluation. The current systematic 
review serves as a timely update of the evidence and identifies full economic evaluations of 
role substitution in primary care.  
 
 
Implications for research and practice  
There is only limited evidence that nurses and allied health professionals can provide a cost-
effective alternative to GPs. This evidence is most convincing for the management of 
common, minor health problems by nurses. However, it is worth acknowledging the majority 
of included studies in this review assessed novel interventions using allied health 
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professionals to replace GP-led care. This broadens the use of role substitution which could 
have implications on evidence as workforce redesign continues to grow. Role substitution is 
becoming commonplace throughout primary care but there is a lack of economic evidence. 
More high quality economic evaluations are needed for all of the different roles that nurses 
and allied health professionals could perform in primary care instead of general practitioners. 
There is a particular lack of evidence for substitution by physiotherapists, occupational 
therapists and physician associates in primary care.  
The substitution of general practitioners by allied health professionals may have the potential 
to reduce costs, but this is greatly reliant on salary differences. Furthermore, consultation 
length and patient recall must also be considered. Although it may seem less costly to employ 
allied health professionals in general practice in terms of their unit costs, their consultation 
lengths may be longer, and they also might be associated with higher patient recall to general 
practice. Consequently, employing allied health professionals to perform roles and duties 
normally completed by GPs may prove more costly overall.   
 
Conclusion 
There is some evidence that the substitution of nurses by GPs when treating common minor 
health problems is cost-effective. There is some evidence that substitution by pharmacists is 
not cost-effective, and no evidence for substitution by therapists or physician associates. In 
order to improve evidence in this field explicit definitions of role substitution are needed. 
More good quality economic evaluations of role substitution using other allied health 
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# ▲ Searches Results  
 
1 (task* adj5 shift*).ti,ab,kw. 2218 
 
 
2 (task* adj5 substitut*).ti,ab,kw. 344 
 
 
3 (role* adj5 shift*).ti,ab,kw. 1528 
 
 
4 (role* adj5 substitut*).ti,ab,kw. 1106 
 
 
5 skill mix*.ti,ab,kw. 820 
 
 
6 exp Delegation, Professional/ 537 
 
 
7 professional delegation.ti,ab,kw. 5 
 
 
8 nurse-doctor substitut*.ti,ab,kw. 2 
 
 
9 nurse-physician substitut*.ti,ab,kw. 1 
 




10 ((position* or responsibility or part or professional or role* or job* or task* or duty or duties or procedure) adj3 
(delegation or allocation or designation or assignment or hand over or handing over or pass on or passing on or 




11 mini doctor*.ti,ab,kw. 12 
 
 
12 exp Physician Assistants/ 5147 
 
 
13 physician associate*.ti,ab,kw. 100 
 
 
14 nurse prescribing.ti,ab,kw. 454 
 
 
15 pharmacist prescribing.ti,ab,kw. 114 
 
 
16 advanced role*.ti,ab,kw. 83 
 
 
17 expanded role*.ti,ab,kw. 1174 
 
 
18 expanded dut*.ti,ab,kw. 148 
 
 
19 Medical-nursing interface.ti,ab,kw. 1 
 
 
20 (Nurs* adj5 medical role*).ti,ab,kw. 19 
 
 
21 nurse-manag*.ti,ab,kw. 3491 
 
 
22 nurse-led.ti,ab,kw. 2755 
 




23 pharmacist-led.ti,ab,kw. 419 
 
 
24 pharmacist-manag*.ti,ab,kw. 358 
 
 
25 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 




26 exp Primary Health Care/ 132154 
 
 
27 primary health care.ti,ab,kw. 22316 
 
 
28 primary care.ti,ab,kw. 92796 
 
 
29 exp Family Practice/ 64219 
 
 
30 exp General Practice/ 71544 
 
 
31 general practice.ti,ab,kw. 34181 
 
 
32 general medical services.ti,ab,kw. 400 
 
 
33 family clinic*.ti,ab,kw. 399 
 
 
34 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 264838 
 
 
35 25 and 34 2937 
 
 




Appendix 2 – PRISMA checklist  
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
3,4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
NA 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
24-26 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
4 
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Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
4,5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
4 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
NA 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  4,5 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
10 
 
Page 1 of 2  
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
NA 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
NA 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
5,7 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
8,9 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  NA 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
10-12 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  10-12 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  NA 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  NA 
DISCUSSION   
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Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
19 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
16-18 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  19 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
19 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 
e1000097. doi:10.1371/journa
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Appendix 3 – Economic evaluation appraisal tool responses (Drummond et al, 2005) 
The Community Pharmacy Medicines Management Project Evaluation Team (2007) 
Checklist question Response  
Was a well-defined question posed in an 
answerable form? 
Yes, to test the hypothesis that the MEDMAN 
service would be cost effective. 
 
Was a comprehensive description of the competing 
alternatives given? 
 
The MEDMAN intervention was well explained, 
however minimal information was given for usual 
care. Does not explain specifics with regards to care 
received from GPs and community pharmacists. 
 
Was the effectiveness of the programmes or 
services established? 
 
The study set out to measure effectiveness 
alongside and economic evaluation. The results 
found no significant effect for the intervention i.e. 
no statistically significant differences between 
groups in any of the outcomes chosen. 
 
Were all the important and relevant costs and 





Were costs and consequences measured accurately 





Were costs and consequences valued credibly? 
 
 




Was an incremental analysis of costs and 






Was allowance made for uncertainty in the 




Did the presentation and discussion of study results 
include all issues of concern to users? 
 
Authors did not state their perspective, therefore 
difficult to determine if all relevant costs and 
consequences were included. Cost were assessed 
from an NHS perspective.  
 
 
The costs and consequences were measured 
accurately in appropriate physical units for the 
research question, however the authors stated they 
used patient records for NHS resource use, but do 
not describe how this resource use was costed. 
 
Yes, costs and consequences were clear and 
appropriately identified for the research question 
 
Follow-up period was 12 months, therefore 
discounting was not required.  
 
 
Authors reported no significant differences in 
outcomes between groups and therefore a cost-
minimisation analysis was conducted, however 
given the lack of significant effect for the 
intervention a cost-consequence analysis may have 
been more appropriate.  
 
Authors did not state any sensitivity analysis they 
only report undertaking secondary outcomes 
analysis – 5 year risk of CV death, patient 
perspectives and patient compliance.  
 
Limitations noted by authors included the choice of 
condition and risk of bias. Additional limitations 
include a lack of sensitivity analysis and choice of 
economic evaluation given the non-significant 
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Checklist question Response  
Was a well-defined question posed in an 
answerable form? 
Yes, to estimate the costs of GPs versus nurse 
practitioners 
 
Was a comprehensive description of the competing 
alternatives given? 
 
Yes, details of the external reference group were 
provided.  
 
Was the effectiveness of the programmes or 
services established? 
 
Yes, this was established from a RCT (Derick van-
Daele et al., 2009). 
 
Were all the important and relevant costs and 




Were costs and consequences measured accurately 




Were costs and consequences valued credibly? 
 
 




Was an incremental analysis of costs and 
consequences of alternatives performed? 
 
 
Was allowance made for uncertainty in the 
establishments of costs and consequences? 
 
 
Did the presentation and discussion of study results 
include all issues of concern to users? 
 
The economic evaluation was conducted from a 
societal perspective. Yes, they identified direct 
costs and identified indirect costs i.e. productivity 
losses measured in terms of sick leave days. 
 
The costs and consequences were measured in 
accurately in appropriate physical units for the 
research question, the authors used National 
information to derive unit costs.  
 
Yes, costs and consequences were clear and 
appropriately identified for the research question. 
 
No follow-up period stated for economic analysis, 
follow-up appointment in the RCT occurred at 2 
weeks, therefore discounting was not required. 
 
No, an incremental analysis of costs and 
consequences was not appropriate as a cost-
minimisation analysis was conducted.  
 
Yes, a sensitivity analysis was conducted varying 
GP salary.  
 
 
The authors stated that due to pragmatic reasons, it 
was not possible to gather data for follow-up 
appointments, length of appointments, or number of 
days absent in the external reference practices. The 
authors noted that the study was not powered to 
assess the impact of adverse events or assess 













Checklist question Response  
Was a well-defined question posed in an 
answerable form? 
Yes, to perform a cost-minimisation analysis of 
community health practitioner services in primary 
care. 
 
Was a comprehensive description of the competing 
alternatives given? 
 
Yes, the study compares costs between community 
health practitioners and physicians. 
 
Was the effectiveness of the programmes or 
services established? 
 
Yes, previous studies have demonstrated that the care 
provided by CHP is comparable to physicians (Kim 
et al., 1985, 1991; Song et al., 1988; Kim, 
1992,1999). 
 
Were all the important and relevant costs and 





Were costs and consequences measured accurately 




Were costs and consequences valued credibly? 
 
 




Was an incremental analysis of costs and 





Was allowance made for uncertainty in the 
establishments of costs and consequences? 
 
Did the presentation and discussion of study results 
include all issues of concern to users? 
 
Yes, they identified direct costs and indirect costs 
including travel and loss of earnings for patients who 
would have had to travel to inner city clinics if the 
CHP model of care was unavailable.   
 
 
The costs and consequences were measured in 
accurately in appropriate physical units for the 
research question, the authors used National 
information to derive unit costs.  
 
Yes, costs and consequences were justified and 
measured appropriately.  
 
Economic analysis was conducted using a 6 month 
time horizon; therefore, discounting rate was 
required.  
 
An incremental analysis of costs and consequences 
was not appropriate, as a cost-minimisation analysis 
was conducted, this was justified as previous research 
showed that CHP provide comparable care to 
physicians.  
 
No sensitivity analysis was conducted.  
 
 
The authors compared their results to other previous 
cost-effectiveness analyses of nurse practitioners and 
make suggestions for future research. The authors 
also note limitations including sample size, self-
reported measured to gather CHP activity for costing 
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Checklist question Response  
Was a well-defined question posed in an 
answerable form? 
Yes, to measure the differences in mean costs and 
effects of a pharmacy-led service for the management 
of chronic pain in primary care compared to GP usual 
care. 
 
Was a comprehensive description of the competing 
alternatives given? 
 
Yes, details of the two interventions were provided 
however usual care was not explained.  
 
Was the effectiveness of the programmes or 
services established? 
 
Yes, this was established in the PIPPC pilot RCT 
(Bruhn et al., 2013). The results found a positive 
benefit for pharmacists prescribing, however authors 
noted that a larger trial was needed.  
 
Were all the important and relevant costs and 





Were costs and consequences measured accurately 





Were costs and consequences valued credibly? 
 
 




Was an incremental analysis of costs and 
consequences of alternatives performed? 
 
 
Was allowance made for uncertainty in the 






Did the presentation and discussion of study results 
include all issues of concern to users? 
 
The economic analysis was undertaken from a NHS 
perspective. Other costs borne by patients, carers and 
productivity losses were deemed outside the remit of 
the NHS perspective, though given the condition 
would argue these would have been relevant.  
 
Yes, costs and consequences were measured 
accurately in appropriate physical units for the 
research question and were sourced from the British 
National Formulary, Scottish Health Service Cost 
book and the Personal Social Services Unit.  
 
Yes, costs and consequences were clearly identified, 
and appropriate for the research question.  
 
Economic analysis was conducted using a 6 month 
time horizon; therefore, discounting rate was not 
required.  
 




Yes, three sensitivity analyses were conducted. 
Authors conducted sensitivity analyses; with imputed 
values for SF-36 scores, excluding hospital inpatient 
costs deemed unassociated with chronic pain, and 
controlling for baseline differences e.g. 
sociodemographic and economic factors.   
 
Limitations noted by authors included high 
uncertainty of results, which should be viewed with 
caution due to small samples size. The authors 
discussed using alternative methods to elicit QALYs. 
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Richardson et al., (2013) 
 
 
Checklist question Response  
Was a well-defined question posed in an 
answerable form? 
Yes, to assess the cost-effectiveness of nurse-led 
pragmatic rehabilitation and supportive listening for 
patients with chronic fatigue syndrome/myalgic 
encephalitis in primary care.  
 
Was a comprehensive description of the competing 
alternatives given? 
 
Details of the two nurse-led interventions were 
provided however no information provided for usual 
care.  
 
Was the effectiveness of the programmes or 
services established? 
 
Clinical effectiveness was based on a three armed RCT 
(Wearden et al., 2010). Cost-effectiveness uses QALYs 
as their measurement of effect.  
 
Were all the important and relevant costs and 








Were costs and consequences measured accurately 




Were costs and consequences valued credibly? 
 
 






Was an incremental analysis of costs and 
consequences of alternatives performed? 
 
 
Was allowance made for uncertainty in the 
establishments of costs and consequences? 
 
Did the presentation and discussion of study results 
include all issues of concern to users? 
 
The economic analysis was conducted from a NHS and 
personal social services perspective. The authors 
assessed costs to the NHS at 2008/09 prices. The study 
assessed HRQol (measured by QALYs), resource use 
and unit costs. The authors also considered private 
expenditures, informal care costs and loss of 
production costs. Social care costs such as family 
support workers were not included.  
 
The costs and consequences were measured accurately 
in appropriate physical units for the research question, 
the authors used NHS prices to calculate costs.   
 
 
Yes, costs and consequences were clear and 
appropriately identified for the research question 
 
Yes, costs and outcomes were discounted at a rate of 
3.5% per year, however the paper was unclear whether 
all follow-up costs and outcomes were discounted or 
only the costs and outcomes that fell outside of the 1 
year time horizon.  
 
Yes, however results found treatment as usual had 
lower costs and better outcomes than both 
interventions.  
 
Yes, authors conducted a complete case analysis as part 
of sensitivity analyses.  
 
Authors concluded that the benefit of the intervention 
was very small, if not non-existent. Authors also noted 
using multiple imputation could have resulted in over 
or under estimation of EQ-5D scores and service use 
costs. Authors compared their results to existing 













Checklist question Response  
Was a well-defined question posed in an 
answerable form? 
Yes, to assess health service resource use of a nurse-led 
disease management for secondary prevention in 
patients with chronic heart disease and heart failure in 
primary care compared with usual care.  
 
Was a comprehensive description of the competing 
alternatives given? 
 




Was the effectiveness of the programmes or 
services established? 
 
Yes, this was established from a RCT (Khunti et al., 
2007).  
 
Were all the important and relevant costs and 




Were costs and consequences measured accurately 
in appropriate physical units? 
 
Were costs and consequences valued credibly? 
 
 






Was an incremental analysis of costs and 
consequences of alternatives performed? 
 
 
Was allowance made for uncertainty in the 
establishments of costs and consequences? 
 
Did the presentation and discussion of study results 
include all issues of concern to users? 
 
The study adopted a patient perspective for outcomes. 
Costs were measured from the perspective of both the 
NHS and patients (including travel costs).  
 
 
The costs and consequences were justified and 
appropriate for the research question.  
 
Yes, costs and consequences were clearly identified, 
and appropriate for the research question.  
 
Follow-up period was 12 months therefore discounting 
was not needed. However, the authors applied a 
discount rate of 6% for equipment and training that 
would have an expected lifespan of more than one 
year. 
 
Yes, the additional costs in the nurse-led clinic service 
compared with the control group were calculated, as 
well as the additional benefits of the service.  
 
Authors used bootstrapping to obtain bootstrapped p 
values for use in the analysis. Sensitivity analysis was 
not reported.  
 
Limitations noted by the authors included low 
participation rates and that all practices were taken 
from one locality. Additionally, authors noted length of 
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